sj-docx-1-ltr-10.1177_13621688211047984 – Supplemental material for Examining the quality of mobile-assisted, video-making task outcomes: The role of proficiency, narrative ability, digital literacy, and motivation

Supplemental material, sj-docx-1-ltr-10.1177_13621688211047984 for Examining the quality of mobile-assisted, video-making task outcomes: The role of proficiency, narrative ability, digital literacy, and motivation by Sanghee Kang and YouJin Kim in Language Teaching Research</p

Additional file 2 of Nomogram for predicting the overall survival of underweight patients with colorectal cancer: a clinical study

Additional file 2. Clinical characteristics of underweight patients after division into training and validation sets

Additional file 1 of Nomogram for predicting the overall survival of underweight patients with colorectal cancer: a clinical study

Additional file 1. Clinicopathological characteristics of non-underweight and underweight patients after propensity score matching

IL-6 induced EMT through STAT3 phosphorylation.

(A) Western blot of HCT 116 and COLO 205 cells treated with 50 ng/mL IL-6. (B) Western blot analysis of HCT 116 and COLO 205 cells after exposure to increasing concentrations of IL-6. Fold-, fold-change; pSTAT3, phosphorylated STAT3; β-actin, beta actin.</p

Effect of metformin on IL-6-induced STAT3 phosphorylation and <i>MMP9</i> expression in the human colon cancer cell line COLO 205.

(A) Western blot analysis of metformin- and IL-6- treated colon cancer cells (HCT 116). (B) Western blot analysis of metformin- and siRNA STAT3 (siSTAT3)—treated colon cancer cells (HCT 116) (C) qPCR analysis of metformin- and IL-6-treated colon cancer cells. Fold-, fold-change; Met, metformin. *p p < 0.01.</p

Gene expression profiles of colon cancer samples stratified by the metformin-treated gene signature of colon cancer cells (GSE67342).

(A) Heatmap of the gene signature from the metformin-treated LoVo colon cancer cells and the control LoVo colon cancer cells (left). The prediction and grouping of TCGA colon cancer patients by the signature from the LoVo cells (right). (B) Kaplan–Meier survival plots of TCGA colon cancer patients by the results of prediction. The metformin-predicted group showed the better survival rate.</p

IL-6 induced EMT in colon cancer cells.

(A) Cell viability assay for colon cancer cell lines. (B) Migration assay for colon cancer cell lines treated with different concentrations of IL-6 for the indicated times. (C) Morphological changes in colon cancer cells upon treatment with IL-6 at the indicated concentrations. Scale bar = 300 μm, HCT 116. *p p < 0.01.</p

Pathway analysis of TCGA patients.

(A) Canonical pathways in TCGA colon cancer patients as assessed by IPA. IL-6 and colorectal metastasis signaling were decreased. (B) GSEA showed that EMT and IL-6 signaling were reduced in the metformin-predicted group significantly. (C) mRNA expression of IL6, FN1, and MMP9 was decreased in the metformin-predicted group (TCGA dataset). *p p < 0.01, JAK: Janus kinase, ES: enrichment score, FDR: false discovery rate.</p

Metformin inhibited IL-6-induced EMT in the human colon cancer cell line.

(A) Migration assay for colon cancer cells incubated with IL-6 and metformin (HCT116). (B) Invasion assay for colon cancer cells (HCT 116). (C) Immunofluorescence confocal microscopy analysis of HCT 116 colon cancer cells treated with IL-6 and metformin. Met, metformin. *p p < 0.01.</p